On this page
Using your own cells sounds obviously safer, and in one respect it is. Autologous stem cell therapy removes the donor entirely — and adds a surgical harvest, several weeks of waiting, and a starting material whose quality depends on your age and health rather than on anyone’s quality control.
What autologous means in practice
Cells taken from you, processed, and returned to you. No donor, no matching question, no dependence on somebody else’s screening.
Two sources dominate. Adipose tissue is collected by a small liposuction, usually from the abdomen or flank under local anaesthetic with sedation. Bone marrow is aspirated from the posterior iliac crest with a needle.
The tissue then goes to a laboratory, where cells are isolated and in most protocols expanded in culture over two to four weeks before being given back.
That expansion step is what makes this a two-visit process, and it is the single biggest practical difference from donor cells — see cord-derived therapy.
The harvest, described honestly
A liposuction harvest is a real procedure. Bruising and soreness at the site for a week or two is normal, and there is a small risk of bleeding, infection or contour irregularity.
Marrow aspiration is quicker but more immediately uncomfortable — the aspiration itself produces a distinctive deep pulling sensation that most people describe as unpleasant rather than painful.
Neither is major surgery. Both are more than the “simple collection” that clinic pages sometimes imply, and both are a second set of risks that donor cells avoid entirely.
Recovery from the harvest also overlaps with the treatment period, which matters for anyone planning to be active soon afterwards or flying home within days.
Expanded or same-day
This is the distinction that matters most and is least often explained.
Expanded preparations culture the cells for weeks to reach a therapeutic number. This is what the trial literature almost always used.
Same-day preparations — stromal vascular fraction from fat, or bone marrow aspirate concentrate — process the tissue in an hour and inject it at the same visit. These contain far fewer mesenchymal cells, mixed with many other cell types, and they are a different product.
A same-day treatment is more convenient, cheaper and not what the randomised trials tested. If a clinic offers treatment in one visit, that is the question to ask about.
What the trials used
A phase III randomised trial used autologous adipose-derived MSCs injected into the knee — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells.
Other randomised work used autologous adipose tissue-derived cells — Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells — and cultured bone marrow-derived cells in knees with cartilage defects — Injectable cultured bone marrow-derived mesenchymal stem cells in varus knees with cartilage defects.
In multiple sclerosis, autologous MSC transplantation has been studied in active progressive disease — Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive MS.
Note how much of this is knees. Autologous evidence outside orthopaedics is thinner than the marketing suggests.
Your age and health are the raw material
MSC yield and proliferative capacity decline with donor age. So does the number of cells recovered per volume of tissue.
Diabetes, obesity, smoking and several chronic conditions all affect the cells that come out — which is an uncomfortable irony, since those conditions are also why people seek treatment.
A clinic proposing autologous treatment for a seventy-five-year-old with metabolic disease should be able to say what yield it expects and what happens if the harvest produces too few cells to use.
That question — what if my own cells are not good enough — is rarely volunteered and always worth asking. The commercially convenient answer is to proceed with whatever was obtained; the honest one is that a low yield may mean the treatment is not worth giving.
The regulatory difference
Minimally manipulated tissue returned to the same person is treated more permissively in many jurisdictions than a donor product or an expanded preparation.
That is part of why same-day autologous preparations are available in places where expanded cells are not — the regulatory category, not the evidence, is what differs.
It also means “this is legal here” may be true of a same-day preparation and not of the expanded one the trials used — see regulation in Thailand.
Risks
Harvest site complications, as above. General injection and infusion risks as elsewhere — see adverse events.
Culture contamination is a real risk in any expanded preparation, which is what release testing exists to catch.
And an autologous preparation is not automatically sterile or safe simply because the cells are yours. Everything that happens between the harvest and the injection is where things go wrong.
This is worth emphasising because “it is your own tissue” is used as a reassurance about the whole process, when it only covers the origin of the material. A contaminated culture of your own cells is no safer than a contaminated culture of anybody else’s.
Choosing between your cells and a donor’s
Younger patients with good tissue and time for two visits have a reasonable case for autologous.
Older patients, those with chronic disease affecting tissue quality, and anyone who can only travel once have a reasonable case for donor cells.
Neither is a moral choice, and a clinic offering only one should be able to say why — sometimes the honest answer is what its laboratory is set up to do — see autologous versus allogeneic.
Frequently asked questions
Is using my own cells safer?
It removes donor and matching questions, and it adds a harvest procedure with its own risks. Safer in one respect, not in every respect.
How long does the whole process take?
Usually weeks, because cells are expanded in culture between harvest and injection. For travelling patients that means two trips or a long stay.
What is a same-day treatment?
Stromal vascular fraction or marrow concentrate, processed in about an hour. Far fewer mesenchymal cells, mixed with other cell types, and not what the trials used.
Does my age affect the cells?
Yes. Yield and proliferative capacity decline with age, and several chronic conditions affect them too — including the ones people seek treatment for.
What if my harvest yields too few cells?
Ask that before paying. It is a real possibility, it is rarely volunteered, and the answer tells you how the clinic handles inconvenient outcomes.
Is the harvest painful?
Liposuction leaves bruising and soreness for a week or two. Marrow aspiration is quicker and more immediately unpleasant. Neither is major surgery.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.